Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
The Policy Exchange has welcomed the introduction of performance related pay (PRP), arguing that opposition to the reforms is misguided. It believes schools now have the flexibility to reward and retain the best teachers, and allows teachers the ability to progress more quickly, potentially reaching £70k after just five years. The NASUWT have come out against the report, arguing that the new system is based on excessive managerial discretion and is designed to pay all teachers less, rather than good teachers more.
Ultimately, the success of PRP will depend on schools implementing well designed, transparent pay systems which measure the contributions teachers make in all spheres of school life, and on schools having the ability to reward their teachers where merited. Here there is consensus between The Policy Exchange and the NASUWT - that PRP should not be used to hold down the overall pay bill. The best schools will be the ones who can incentivise and reward excellence on a limited budget.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Senior Associate
Select which mailings you would like to receive from us.
Sign up